Acute estradiol treatment reduces skeletal muscle protein breakdown markers in early- but not late-postmenopausal women
| Autor: | Catherine M. Jankowski, Young-Min Park, Shauna S. Runchey, Chounghun Kang, Benjamin F. Miller, Amy C. Keller, Wendy M. Kohrt, Rachael E. Van Pelt, Kerrie L. Moreau |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Time Factors Clinical Biochemistry Muscle Proteins 030209 endocrinology & metabolism Biochemistry Article 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine Myosin medicine Humans Muscle Skeletal Molecular Biology Protein kinase B Retrospective Studies Pharmacology Estradiol business.industry Organic Chemistry Estrogen Receptor alpha Skeletal muscle Middle Aged medicine.disease Tropomyosin Menopause Postmenopause Protein catabolism medicine.anatomical_structure Gene Expression Regulation 030220 oncology & carcinogenesis Sarcopenia FOXO3 Female business Biomarkers |
| Zdroj: | Steroids |
| ISSN: | 1878-5867 |
| Popis: | OBJECTIVES: Menopause and decline in estradiol (E(2)) may contribute to sarcopenia (i.e., age-related decline in muscle mass and strength) in women. E(2) may directly impact skeletal muscle protein breakdown via estrogen receptor (ER) signaling, primarily ERα. It is not yet known whether: 1) E(2) regulates pathways of skeletal muscle protein breakdown; 2) E(2)-mediated changes in protein breakdown markers are associated with ERα activation and insulin sensitivity; and 3) the effects of E(2) on protein breakdown markers differ by increasing time since menopause. STUDY DESIGN: We studied 27 women who were ≤6 years past menopause (early postmenopausal, EPM; n=13) or ≥10 years past menopause (late postmenopausal, LPM; n=14). Fasted skeletal muscle samples were collected following 1 week of transdermal E(2) or placebo treatment in a randomized cross-over design. MAIN OUTCOME MEASURES: We analyzed for cytosolic protein content of the: 1) structural proteins myosin heavy chain (MHC) and tropomyosin; and 2) protein regulatory markers: protein kinase B (Akt), muscle-specific ring finger protein1 (MuRF1), atrogin1, and forkhead box O3 (FOXO3) using Western blot. RESULTS: In response to acute E(2), FOXO3 activation (dephosphorylation) and MuRF1 protein expression decreased in EPM but increased in LPM women (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect